|
US5736577A
(en)
*
|
1995-01-31 |
1998-04-07 |
Sepracor, Inc. |
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
|
|
US3864388A
(en)
*
|
1970-12-29 |
1975-02-04 |
Sumitomo Chemical Co |
Alkynyl esters of {60 -alkoxy-{60 -phenyl alkenoic acid
|
|
US5036107A
(en)
*
|
1986-06-27 |
1991-07-30 |
Marion Merrell Dow Inc. |
1,7-substituted heptyn-2-ones and use
|
|
US4957941A
(en)
*
|
1987-11-16 |
1990-09-18 |
United Pharmaceuticals, Inc. |
Anti-spasmdoic agents having an acetylenic bond
|
|
IL91377A
(en)
*
|
1988-09-14 |
1996-09-12 |
Nippon Shinyaku Co Ltd |
Derivatives of botinylamine glycolate
|
|
US5677346A
(en)
*
|
1995-01-31 |
1997-10-14 |
Sepracor, Inc. |
Treating urinary incontinence using (S)-desethyloxybutynin
|
|
US5532278A
(en)
*
|
1995-01-31 |
1996-07-02 |
Sepracor, Inc. |
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
|
|
WO1998001125A2
(en)
*
|
1996-07-09 |
1998-01-15 |
Sepracor, Inc. |
Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
|
|
US5973182A
(en)
*
|
1998-10-22 |
1999-10-26 |
Sepracor Inc. |
Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters
|
|
US6140529A
(en)
*
|
1998-10-22 |
2000-10-31 |
Sepracor Inc. |
Synthesis of optically active cyclohexylphenylglycolate esters
|
|
EP2322170A1
(en)
*
|
2000-04-26 |
2011-05-18 |
Watson Pharmaceuticals, Inc. |
Minimizing adverse experience associated with oxybutynin therapy
|
|
US7179483B2
(en)
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
SG168451A1
(en)
|
2001-10-26 |
2011-02-28 |
Upjohn Co |
Quarternary ammonium compounds and their use as antimuscarinic agents
|
|
MXPA05000434A
(es)
|
2002-07-08 |
2005-04-19 |
Ranbaxy Lab Ltd |
Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
|
|
WO2004014853A1
(en)
*
|
2002-07-31 |
2004-02-19 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
|
AU2002321711A1
(en)
*
|
2002-08-09 |
2004-02-25 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
|
|
DE60231341D1
(de)
*
|
2002-08-23 |
2009-04-09 |
Ranbaxy Lab Ltd |
Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
|
|
TW200412945A
(en)
|
2002-10-25 |
2004-08-01 |
Upjohn Co |
Quaternary ammonium compounds
|
|
AU2002353286A1
(en)
|
2002-12-10 |
2004-06-30 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
|
|
AU2002347552A1
(en)
*
|
2002-12-23 |
2004-07-14 |
Ranbaxy Laboratories Limited |
1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
|
|
US7501443B2
(en)
*
|
2002-12-23 |
2009-03-10 |
Ranbaxy Laboratories Limited |
Flavaxate derivatives as muscarinic receptor antagonists
|
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
AU2003214520A1
(en)
*
|
2003-04-09 |
2004-11-01 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
US7592359B2
(en)
*
|
2003-04-10 |
2009-09-22 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
EP1615887A1
(en)
|
2003-04-10 |
2006-01-18 |
Ranbaxy Laboratories, Ltd. |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
WO2004089900A1
(en)
*
|
2003-04-11 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Azabicyclo derivatives as muscarinic receptor antagonists
|
|
US20080319002A1
(en)
*
|
2004-06-16 |
2008-12-25 |
Ranbaxy Laboratories Limited |
Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
|
|
WO2006018708A2
(en)
*
|
2004-08-19 |
2006-02-23 |
Ranbaxy Laboratories Limited |
Pyrrolidine derivatives as muscarinic receptor antagonists
|
|
WO2006032994A2
(en)
*
|
2004-09-24 |
2006-03-30 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
EP1797040A1
(en)
*
|
2004-09-29 |
2007-06-20 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
EP1828174A1
(en)
*
|
2004-11-19 |
2007-09-05 |
Ranbaxy Laboratories Limited |
Azabicyclic muscarinic receptor antagonists
|
|
EP1828126A1
(en)
*
|
2004-12-15 |
2007-09-05 |
Ranbaxy Laboratories Limited |
Acid addition salts of muscarinic receptor antagonists
|
|
WO2006117754A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
|
|
RU2008119323A
(ru)
|
2005-10-19 |
2009-11-27 |
Рэнбакси Лабораториз Лимитед (In) |
Фармацевтические композиции мускаринового рецептора
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
WO2009122429A2
(en)
*
|
2008-02-04 |
2009-10-08 |
Matrix Laboratories Limited |
Crystalline oxybutynin and process for preparing the same
|
|
AU2011245499B2
(en)
|
2010-04-30 |
2014-09-25 |
Merck Sharp & Dohme Corp. |
Novel beta 3 adrenergic receptor agonists
|
|
SG187689A1
(en)
|
2010-08-03 |
2013-03-28 |
Altherx Inc |
Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
|
|
US9907767B2
(en)
|
2010-08-03 |
2018-03-06 |
Velicept Therapeutics, Inc. |
Pharmaceutical compositions and the treatment of overactive bladder
|
|
AR089957A1
(es)
|
2012-02-09 |
2014-10-01 |
Altherx Inc |
Combinaciones farmaceuticas, combinaciones sinergicas
|
|
HK1245117A1
(zh)
|
2014-12-03 |
2018-08-24 |
Velicept Therapeutics, Inc. |
使用调节释放索拉贝隆用於下尿路症状的组合物和方法
|
|
EP3365321B1
(en)
|
2015-10-23 |
2023-12-13 |
B3AR Therapeutics, Inc. |
Solabegron zwitterion and uses thereof
|
|
NZ766673A
(en)
|
2018-01-30 |
2025-08-29 |
Apnimed Inc Delaware |
Methods and compositions for treating sleep apnea
|